GSK raised its full-year guidance after second quarter core earnings rose 13%, helped by higher sales in oncology, HIV and its general medicines portfolio.
Related Posts
Insurers Pocketed $50 Billion From Medicare for Diseases No Doctor Treated
Questionable diagnoses of HIV and other maladies triggered extra Medicare Advantage payments. “It’s anatomically impossible,” said one doctor about some cataract diagnoses.
Harley Will Ride or Die With the Graybeards
Milwaukee-based company focuses on high-end motorcycles, but some say it isn’t cultivating the next generation of buyers. ’You get older, you actually realize it’s a […]
Warner Bros. Discovery Posts Nearly $10 Billion Loss
The loss includes a $9.1 billion impairment charge tied to the plunging value of its linear networks.